VIP (Vasoactive Intestinal Peptide): Strong Biology, Weak Human Proof
VIP has compelling anti-inflammatory mechanisms in animals, but rigorous human trials have largely failed. Here's the honest evidence picture.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-17Strong, reproducible anti-inflammatory and vasodilatory biology in animal and in-vitro models, but rigorous human trials were negative or halted for futility (inhaled-VIP phase II in pulmonary hypertension; IV-aviptadil in COVID-19); no approved product exists for the immune/anti-inflammatory uses discussed, and the popular intranasal CIRS use rests on a single uncontrolled case series.
Established VPAC1/VPAC2 receptor biology: a coherent, well-supported anti-inflammatory (NF-kB suppression, tolerogenic dendritic cells, Th2/Treg shift) and vasodilatory mechanism, though the immune data are largely animal/in-vitro.
Extensive, reproducible animal and in-vitro anti-inflammatory data across models of rheumatoid arthritis, osteoarthritis and Sjögren's disease.
The rigorous human trials are negative: an inhaled-VIP phase II in pulmonary hypertension missed its endpoint and the IV-aviptadil COVID-19 RCT (TESICO) was halted for futility; positive signals are small, open-label or acute.
No controlled demonstration of clinical benefit for the immune/anti-inflammatory uses; the popular intranasal CIRS use rests on one uncontrolled, non-indexed case series.
Partial: vasodilatory adverse effects (hypotension, flushing, tachycardia, diarrhoea) are characterised in trials, but chronic intranasal/systemic and long-term safety are not established, and compounded product is not quality-assured.
Reached formal trials (aviptadil) across several indications, but development was largely not advanced after negative/futile results.
Moderate: the rigorous human trials consistently underwhelmed, and the mechanism has not translated into demonstrated benefit for these uses.
No approved VIP product for the immune/CIRS uses; aviptadil held FDA Fast Track / Expanded Access but was never approved, and intranasal VIP is a compounded preparation.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A neuropeptide with strong, reproducible anti-inflammatory and vasodilatory biology in animal and in-vitro models, but rigorous human trials were negative or halted for futility (inhaled-VIP in pulmonary hypertension; IV-aviptadil in COVID-19); the popular intranasal CIRS use rests on a single uncontrolled case series.
Safety snapshot
A potent vasodilator whose adverse effects (hypotension, flushing, tachycardia, diarrhoea) follow from its mechanism; there is no quality-assured product for immune/CIRS use, and chronic intranasal/systemic safety is not established.
Regulatory & legality
No approved VIP product exists for the immune/anti-inflammatory uses; aviptadil held Fast Track / Expanded Access but was never approved, and intranasal VIP is a compounded preparation.
Where claims can exceed the evidence
The mechanism has not translated into demonstrated clinical benefit for these uses; the CIRS diagnosis itself is not recognised in mainstream medicine.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Vasoactive Intestinal Peptide (VIP) is one of those compounds where the gap between the laboratory story and the clinical reality is enormous — and worth being honest about. It is a 28-amino-acid neuropeptide with a genuinely impressive, reproducible track record in animal and test-tube models: it calms inflammation, nudges the immune system towards tolerance, and relaxes smooth muscle to open up blood vessels and airways.
That biology generated real clinical interest. A synthetic version, aviptadil (branded RLF-100 / ZYESAMI), was put through formal trials for pulmonary arterial hypertension (PAH), sarcoidosis, and critical COVID-19. The results were largely disappointing. Meanwhile, in the chronic inflammatory response syndrome (CIRS) / mould-illness community, intranasal VIP has become a popular "final step" protocol — but that use rests on a single uncontrolled case series, not controlled trials.
The short version: strong mechanistic and animal data, no approved indication for these uses, and human efficacy data that range from modest to outright negative in the most rigorous studies.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
PNC-27: The Cancer-Killing Peptide That Hasn't Met a Human Trial
A plain-English, evidence-first look at PNC-27: a clever pore-forming anti-cancer peptide with two decades of lab work but zero registered human trials.
Thymalin: A Soviet-Era Thymus Peptide for Immune Rejuvenation, Examined
Thymalin is a Russian thymus-peptide immunomodulator with intriguing COVID and ageing data — but the evidence comes almost entirely from one research group.
Thymosin Alpha-1: The Immune Modulator With a Real Clinical Track Record
Thymosin alpha-1 has decades of human use and 30+ trials behind it. We unpack where the evidence is genuinely strong, where it is thin, and what it actually does.